Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 5/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.38 |
| ▸ | SCN1A | P35498 | 2/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28273630 | 0.93 | THRB (0.55) | ALDH1A1THRBTSHRCYP2D6LMNA | |
| SCHEMBL14874 | 0.93 | THRB (0.55) | ALDH1A1THRBTSHRCYP2D6LMNA | |
| SCHEMBL22684899 | 0.91 | THRB (0.53) | ALDH1A1THRBTSHRCYP2D6LMNA | |
| Hydrochloric Acid SCHEMBL2847352 | 0.91 | THRB (0.53) | ALDH1A1THRBTSHRCYP2D6LMNA | |
| SCHEMBL9800939 | 0.91 | THRB (0.53) | ALDH1A1THRBTSHRCYP2D6LMNA | |
| Acetic Acid SCHEMBL10336380 | 0.89 | THRB (0.52) | ALDH1A1THRBTSHRCYP2D6LMNA | |
| Chloromethane SCHEMBL1128072 | 0.89 | THRB (0.52) | ALDH1A1THRBTSHRCYP2D6LMNA | |
| SCHEMBL10697522 | 0.89 | THRB (0.55) | ALDH1A1THRBTSHRCYP2D6LMNA | |
| SCHEMBL4635102 | 0.89 | TSHR (0.65) | ALDH1A1THRBTSHRCYP2D6CYP1A2 | |
| Boric Acid SCHEMBL8763859 | 0.88 | THRB (0.50) | ALDH1A1THRBTSHRCYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4333815-A1 | TASTE MASKED COMPOSTIONS OF 2,4,6-TRIFLUORO- N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2- YLJ-BENZAMIDE HEMISUCCINATE, AND ORALLY DISENTEGRATING TABLET COMPRISING THE SAME | ELI LILLY AND COMPANY (US) | 2024-03-13 | — | — | EP | claimed |
| WO-2022236004-A1 | TASTE MASKED COMPOSTIONS OF 2,4,6-TRIFLUORO- N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2- YLJ-BENZAMIDE HEMISUCCINATE, AND ORALLY DISENTEGRATING TABLET COMPRISING THE SAME | ELI LILLY AND COMPANY (US) | 2022-11-10 | — | — | WO | claimed |
| EP-4482081-A1 | ENVIRONMENTAL ATTRIBUTES FOR PHARMACEUTICAL EXCIPIENTS | BASF SE (DE) | 2024-12-25 | — | — | EP | disclosed |
| US-12023226-B2 | Methods and devices for skin tightening | CYTRELLIS BIOSYSTEMS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240197661-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-06-20 | — | — | US | disclosed |
| US-20240165035-A1 | COATED SOLID PHARMACEUTICAL PREPARATION | SSP CO., LTD. (JP) | 2024-05-23 | — | — | US | disclosed |
| WO-2024027794-A1 | TASTE-MASKING MICROSPHERE, PREPARATION PROCESS THEREFOR, AND USE THEREOF | 哈尔滨市康隆药业有限责任公司 | 2024-02-08 | — | — | WO | disclosed |
| US-20240024249-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A METHYL HYDROGEN FUMARATE PRODRUG | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| EP-4308094-A1 | COATED SOLID PHARMACEUTICAL PREPARATION | SSP Co., Ltd. (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-20230310222-A1 | METHODS AND DEVICES FOR SKIN TIGHTENING | D1 CAPITAL PARTNERS, L.P. | 2023-10-05 | — | — | US | disclosed |
| WO-2023176783-A1 | SOLID COMPOSITION | 第一三共ヘルスケア株式会社 | 2023-09-21 | — | — | WO | disclosed |
| US-20120059054-A1 | Use Of Copolymers Based On Amino-Containing Polymers As Matrix Binders In Preparing Active Compound-Containing Granules And Administration Forms | BASF SE (DE) | 2012-03-08 | — | — | US | disclosed |
| WO-2011051155-A2 | STABLE PROTECTIVE COATINGS FOR PHARMACEUTICAL DOSAGE FORMS | BASF SE (DE) | 2011-05-05 | — | — | WO | disclosed |
| US-6423460-B1 | INORGANIC POLYMER AND ORGANOMETALLIC POLYMER BLEND OF | XEROX CORPORATION | 2002-07-23 | — | — | US | disclosed |
| US-6051354-A | MIXING IN A HIGH SHEAR DEVICE A CARRIER CORE AND A CARRIER COATING, AND WHEREIN SAID HIGH SHEAR DEVICE CONTAINS IMPELLERS. | XEROX CORPORATION (US) | 2000-04-18 | — | — | US | disclosed |
| US-6037091-A | Carrier with ferrocene containing polymer | XEROX CORPORATION (US) | 2000-03-14 | — | — | US | disclosed |
| EP-0232442-B1 | IMPROVED BLOOD-PURIFYING MEMBRANE AND PROCESS FOR PREPARATION THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1989-04-26 | — | — | EP | disclosed |
| US-4787977-A | REGENERATED CELLULOSE WITH AMINO CONTAINING POLYMERIC COATING | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1988-11-29 | — | — | US | disclosed |
| EP-0232442-A1 | Improved blood-purifying membrane and process for preparation thereof | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1987-08-19 | — | — | EP | disclosed |
| US-4255308-A | A DISPERSION COMPRISING A BINDER OF A METHYL METHACRYLATE POLYMER, A DISPERSANT OF AN ACRYLIC TERPOLYMER, AND A GRAFT POLYMER OF THE TWO; FINISHES FOR CARS AND TRUCKS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024249-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A METHYL HYDROGEN FUMARATE PRODRUG | FH, MGMT, CYP4F2 | ALDH1A1 1240/4885THRB 4233/4885TSHR 4391/4885 |
| US-20240197661-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | MGMT, MTHFD2, PHF2 | ALDH1A1 2175/4885THRB 4158/4885TSHR 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.